HGS cancer drug fails another mid-stage trial

Human Genome Sciences (HGSI) says that a combination of Velcade and its experimental cancer drug mapatumumab (HGS-ETR1) flunked a mid-stage trial for multiple myeloma, with the data failing to demonstrate an improvement over Velcade alone. "The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs. the control group receiving bortezomib alone, and showed that mapatumumab was well tolerated in this study," HGS said in a...